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DiGeorge Critical Region 8 (DGCR8) Is a
Double-cysteine-ligated Heme Protein*□
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All known heme-thiolate proteins ligate the heme iron using
one cysteine side chain. We previously found that DiGeorge
Critical Region 8 (DGCR8), an essential microRNA processing
factor, associates with heme of unknown redox state when overexpressed in Escherichia coli. On the basis of the similarity of the
450-nm Soret absorption peak of the DGCR8-heme complex to
that of cytochrome P450 containing ferrous heme with CO
bound, we identified cysteine 352 as a probable axial ligand in
DGCR8. Here we further characterize the DGCR8-heme interaction using biochemical and spectroscopic methods. The
DGCR8-heme complex is highly stable, with a half-life exceeding 4 days. Mutation of the conserved proline 351 to an alanine
increases the rate of heme dissociation and allows the DGCR8heme complex to be reconstituted biochemically. Surprisingly,
DGCR8 binds ferric heme without CO to generate a hyperporphyrin spectrum. The electronic absorption, magnetic circular
dichroism, and electron paramagnetic resonance spectra of the
DGCR8-heme complex suggest a ferric heme bearing two cysteine ligands. This model was further confirmed using selenomethionine-substituted DGCR8 and mercury titration. DGCR8
is the first example of a heme-binding protein with two endogenous cysteine side chains serving as axial ligands. We further
show that native DGCR8 binds heme when expressed in eukaryotic cells. This study provides a chemical basis for understanding the function of the DGCR8-heme interaction in microRNA
maturation.

Heme proteins use a variety of amino acids to serve as the
axial ligands (the fifth and possibly sixth ligands) for the heme
iron. In many cases, such as with hemoglobins (1), soluble guanylate cyclases (2) and heme oxygenases (3), an imidazole moiety of a histidine side chain acts as the fifth ligand. Another
major class of heme-binding proteins, exemplified by the cytochrome P450 proteins (4), chloroperoxidases (5), and nitric
oxide synthases (6), uses a cysteine side chain as the fifth ligand.

* This project is supported, in whole or in part, by National Institutes of Health
Grants GM080563 (to F. G.) and HL065217 (to J. N. B.).
The on-line version of this article (available at http://www.jbc.org) contains
supplemental Figs. S1–S4, Tables S1 and S2, and references.
1
To whom correspondence may be addressed: 1101 University Ave., Madison, Wisconsin 53706. Fax: 608-262-6143; E-mail: burstyn@chem.wisc.
edu.
2
To whom correspondence may be addressed: 611 Charles E. Young Dr. E.,
202 Boyer Hall, Los Angeles, CA 90095. Fax: 310-206-7286; E-mail: fguo@
mbi.ucla.edu.

This class is called heme-thiolate proteins (7). The functions of
these axial ligands include enhancing the affinity and specificity
of the protein-heme interaction, modulating the redox properties of the heme, and enabling the heme to serve as catalysts,
transporters, or sensors (8, 9). Often, the sixth ligand of the iron
in heme is a substrate, a cargo, or a protein moiety that modulates the biological activities of the protein.
We have previously found that the RNA-binding partner
protein of the Drosha nuclease in humans, called DiGeorge
Critical Region 8 (DGCR8)3 (or Pasha for its insect and worm
homologs), is a heme-binding protein (10). DGCR8 (11–14)
and Drosha (15) are responsible for processing primary transcripts of microRNAs (pri-miRNAs) into precursor miRNAs in
the first step of the miRNA maturation pathway in animals
(16 –18). A truncated but active form of DGCR8 named NC1,
containing residues 276 –751 of this 773-amino acid protein
(Fig. 1A), exists as a heme-bound dimer and heme-free monomer when overexpressed in Escherichia coli (10). The hemebound NC1 dimer is more active in reconstituted pri-miRNA
processing assays than the heme-free monomer, indicating that
heme is important for the function of DGCR8. Heme-bindingdeficient NC1 mutants are defective in pri-miRNA processing
in vitro (10, 19). DGCR8 binds heme through a heme-binding
domain (HBD, amino acids 276 – 498) that can be expressed in
a soluble, heme-bound form in the absence of other domains
(Fig. 1A) (19). The HBD is not required for binding and processing pri-miRNAs in vitro and most likely serves a regulatory
function (10). The N-terminal region of the HBD (amino acids
276 –353) is a dimerization subdomain that includes a WW
motif, which is most often involved in binding proteins with
proline-containing sequences (19). The crystal structure of this
domain, in the absence of heme, revealed a novel use of its WW
motif for dimerization (19). Importantly, the structure showed
that all the residues known to be essential for association with
heme, including Cys-352 and Trp-329 (the second W in the
WW motif) from both subunits, cluster on a common surface
that presumably directly contacts heme.

□
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The abbreviations used are: DGCR8, DiGeorge Critical Region 8; miRNA,
microRNA; pri-miRNA, primary transcripts of microRNA; HBD, heme-binding domain; ␦-ALA, ␦-aminolevulinic acid; SEC, size exclusion chromatography; hHBDC430S, human DGCR8 HBD-His6 C430S mutant protein; EPPS,
4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid; ⑀, extinction coefficient; MCD, magnetic circular dichroism; MeHgAc, methylmercury acetate;
SeMet, selenomethionine.
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DGCR8 Is a Double-cysteine-ligated Heme Protein
DGCR8 appears to belong to a previously uncharacterized
family of heme proteins. Heme-bound NC1 exhibits electronic
absorption peaks at 450, 367, and 556 nm, with the 367-nm
peak almost as intense as the strongest 450-nm peak. The Soret
peak at ⬃450 nm is characteristic for heme-binding proteins
with a thiolate ligand contributed by a cysteine side chain (20,
21). The Soret peak of the heme-thiolate protein cytochrome
P450 red-shifts to ⬃450 nm when the iron in heme is reduced to
the ferrous state and CO binds as the sixth ligand (22). Consistent with this precedent, mutation of a conserved Cys-352 to
alanine, serine, or histidine in NC1 abolishes heme binding,
implying that Cys-352 is an axial ligand of the iron in the heme
(10). However, there is no obvious source of CO in the purification and storage of recombinant NC1. Furthermore, in cytochrome P450, ferrous heme ligated by a cysteine thiolate trans
to CO exhibits a spectrum with the 366-nm band substantially
less intense than the ⬃450-nm peak. Our understanding of the
DGCR8-heme interaction has been limited by a lack of in vitro
heme-binding assays, as incubation of the heme-free monomer
with heme does not produce the heme-bound dimer. In addition, there does not appear to be any interchange between the
dimer and monomer species in vitro, regardless whether heme
is present.
In this study, we used a diverse set of methods to examine the
redox and ligation states of the heme in DGCR8. A mutant
NC1, P351A, was shown to reversibly bind heme, forming a
reconstituted complex that displays an electronic absorption
spectrum similar to that of the wild-type protein. Heme dissociation and association assays revealed heretofore unknown
properties of DGCR8. Most notably, DGCR8 stably binds ferric
heme and exhibits the 450-nm Soret peak in the absence of CO.
Spectroscopic characterization of the DGCR8 HBD reveals
unique features associated with the uncommon heme coordination environment, including a narrow g anisotropy in the
EPR spectrum. These results, along with SeMet substitution
and mercury titration experiments, demonstrate that DGCR8
is a novel heme-binding protein with two cysteine side chains as
axial ligands. Additionally, we show that DGCR8 binds heme
when expressed in eukaryotic cells. The unique interaction
between DGCR8 and heme provides the biochemical basis for
understanding a potential mechanism for regulating miRNA
maturation.

EXPERIMENTAL PROCEDURES
Reagents—Horse skeletal muscle apomyoglobin was from
Sigma-Aldrich (St. Louis, MO). Hemin and ␦-ALA were from
MP Biomedicals (Solon, OH). L-(⫹)-selenomethionine was
from Acros Organics (Morris Plains, NJ). Methylmercury(II)
acetate (MeHgAc) was purchased as a part of a heavy atom
screening kit from Hampton Research (Aliso Viejo, CA). Caution: MeHgAc is extremely toxic and should be handled with
great care.
Plasmids—Site-directed mutagenesis of NC1 and human
DGCR8 HBD-His6 in the pET-24a⫹ vector was carried out
using the standard four-primer PCR method (19). The insect
cell expression plasmid for His6-NC1 was generated by cloning
the coding sequence for residues 276 –751 of human DGCR8
into the pFastBac-HTb vector between the BamHI and EcoRI
MAY 13, 2011 • VOLUME 286 • NUMBER 19

sites. The cDNA clone of the DGCR8 homolog from Xenopus
laevis (frog) was obtained from Open Biosystems. The HBD
coding region of the frog DGCR8 (amino acids 278 – 498) was
amplified using PCR and was inserted into the pET-24a⫹ vector between the NdeI and NotI sites. The coding sequences of
all plasmids were verified through sequencing.
Protein Expression and Purification—NC1 constructs were
expressed and purified as described previously (10). The hemebound proteins were expressed with 1 mM ␦-ALA added at
induction. The purification procedure started with two rounds
of ion exchange chromatography using a SP-Sepharose HP column, and the monomer and dimer species were separated using
size exclusion chromatography (SEC) and a Superdex 200
10/300 GL column (GE Healthcare).
The frog DGCR8 HBD-His6 was expressed in E. coli strain
BL21(DE3) CodonPlus (Strategene) and purified using Ni-affinity chromatography followed by SEC, as reported previously
for human HBD-His6 (19). The purified protein was exchanged
into desired buffers for spectroscopic studies, as indicated in
the figure legends, using centrifugal concentrators with a
molecular mass cut-off of 30 kDa. SeMet-labeled frog DGCR8
HBD-His6 was expressed using the same vector, host strain, and
procedure as described by Van Duyne et al. (23). Briefly, E. coli
were cultured in M9 minimal medium containing no methionine. Six other amino acids known to inhibit methionine biosynthesis were added to the culture 15 min prior to induction.
In addition, 40 M FeCl3 and 1 mM ␦-ALA were added to the
medium at induction to increase the synthesis of heme and the
yield of the HBD-heme complex. SeMet-labeled HBD-His6 was
expressed at 25 °C overnight (⬃16 h) and purified using the
same procedure as that for the unlabeled protein.
The human DGCR8 HBD-His6 C430S mutant protein
(hHBDC430S, used in a mercury titration experiment) was
expressed and purified using the same procedure as described
for the wild-type protein (19), except that the SEC was performed in the absence of reducing reagents. Prior to the mercury titration experiments, the purified HBD mutant was concentrated and exchanged into a buffer containing 50 mM EPPS
(pH 8.0) and 400 mM NaCl, using a centrifugal concentrator
with a molecular mass cut-off of 30 kDa. The extinction coefficient of the heme-bound hHBDC430S protein (⑀280 nm ⫽ 31
mM⫺1 cm⫺1) was determined experimentally by measuring its
absorption at 280 nm and its protein concentration using the
Micro BCA protein assay kit (Pierce).
The His6-NC1 protein was expressed in Sf9 cells following
the instructions in the Bac-to-Bac system (Invitrogen). His6NC1 was purified using Ni-affinity chromatography followed
by cation exchange chromatography using a SP column (GE
Healthcare). The purified protein fractions were pooled, concentrated, and exchanged in a storage buffer containing 20 mM
Tris (pH 8.0), 400 mM NaCl, and 1 mM DTT using an Ultra-4
concentrator with a 30-kDa molecular mass cut-off. Sf9 cellexpressed His6-NC1 was analyzed using a Superdex 200 10/300
GL column, and the absorption at 260, 280, and 450 nm was
monitored (Fig. 9B). The size exclusion chromatogram was
baseline-adjusted using the Unicorn software (version 5.0, GE
Healthcare). The ratio of the absorption by heme and by protein
(the RZ value) was used to calculate the percentage of His6-NC1
JOURNAL OF BIOLOGICAL CHEMISTRY
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occupied by heme using the extinction coefficients (⑀) 58 mM⫺1
cm⫺1 for heme (450 nm) and 53 mM⫺1 cm⫺1 for each His6-NC1
subunit (280 nm). The ⑀450 nm of insect cell-expressed His6NC1 was assumed to be the same as that of the untagged NC1
expressed in E. coli (10). The ⑀280 nm was calculated from the
His6-NC1 sequence using the program ProtParam on the
ExPASy proteomics server provided by the Swiss Institute of
Bioinformatics (24).
Heme Dissociation and Association Assays—Hemin chloride
was dissolved in 1.4 M NaOH at 100 mM concentration and
incubated at room temperature for ⬎30 min. This concentrated solution was then diluted in water to give a 100 M stock
solution. All reactions were carried out in 20 mM Tris buffer
(pH 8.0), 400 mM NaCl, and 1 mM DTT, unless otherwise
specified.
Electronic Absorption Spectroscopy—The spectra were recorded at 25 °C using either a DU800 spectrophotometer
(Beckman-Coulter, bandwidth ⱕ 1.8 nm) in sealed cuvettes
(Figs. 1– 4, 8, 9), a DU500 spectrophotometer (BeckmanCoulter, bandwidth ⬍ 4.5 nm) (Fig. 3D), or a double-beam Varian Cary 4 Bio spectrophotometer (Agilent Technologies) with
its spectral bandwidth set to 0.5 nm (Figs. 5 and 7B).
MCD Spectroscopy—MCD spectra were recorded on a Jasco
J-715 circular dichroism spectropolarimeter with the sample
compartment modified to accommodate an SM-4000 – 8T
magnetocryostat (Oxford Instruments). The buffer used for the
MCD samples was 50 mM EPPS and 400 mM NaCl (pH 8.0) with
⬃55% (v/v) glycerol present in the final sample. Glycerol was
introduced to the protein and stirred with a syringe until the
solution was homogenous. Glycerol had no effect on the electronic absorption spectra at room or liquid-helium temperatures. Samples were transferred via gas-tight syringes into cells,
flash-frozen, and stored in liquid N2. MCD spectra were taken
over a temperature range from 4 to 50 K. The MCD signal at
each temperature was recorded at ⫾7 T. Negative polarity
data were subtracted from positive polarity data to remove
circular dichroism contributions, and the resulting spectrum was divided by 2. Magnetic saturation curves were generated from data taken at 448 nm, and data were normalized
to the most intense MCD data point (7 T, 2.5 K).
EPR Spectroscopy—X-band electron paramagnetic resonance spectra were collected on a Bruker ELEXSYS E500
equipped with an Oxford ESR 900 continuous flow liquid
helium cryostat and an Oxford ITC4 temperature controller
maintained at 10 K. The microwave frequency was monitored
using an EIP model 625A CW microwave frequency counter.
Protein samples were prepared as indicated in the figure legends. Samples were transferred to a quartz EPR tube via smallbore tubing connected to a gas-tight syringe and were frozen in
liquid N2. Samples of 150 l had a final concentration of ⬃150
M heme. For all samples, scans of 0 –10,000 G revealed no
signals other than those reported.
MALDI-TOF Mass Spectrometry—Native and SeMet-labeled
frog DGCR8 HBD-His6 were dissolved in a 1:9 (v/v) ratio with a
mixture containing 70% (v/v) acetonitrile, 0.1% (v/v) trifluoroacetic acid, and saturating concentration of sinapinic acid
(Fluka). The samples were analyzed using a Voyager-DE STR
MALDI-TOF mass spectrometer (Applied Biosystems) oper-
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ated in a linear mode with positive polarity. The mass accuracy
in this mode is ⱕ ⫾ 0.05% for myoglobin (16,952 Da). The m/z
range from 10,000 to 70,000 was monitored.
Mercury Titration of Cysteines in Human HBD—A stock
solution of MeHgAc was prepared at a 0.5 mM concentration in
50 mM EPPS (pH 8.0) and 400 mM NaCl. (Caution: MeHgAc is
volatile and extremely toxic. The stock solution was prepared in
a fume hood.) The MeHgAc stock was added to 200 l of 10-M
hHBDC430S dimer solution in 2-l increments. The solution
was incubated at 25 °C for 10 min before the electronic absorption spectra were recorded. After the mercury titration, 30 l of
apomyoglobin stock solution (80 M) was added, and the electronic absorption spectrum was recorded.
Reconstituted pri-miRNA Processing Assays—The procedure
was described previously (10). Briefly, the 150-nucleotide primiR-30a was uniformly labeled with 32P and was incubated
with recombinant Drosha and His6-NC1 at 37 °C for 45 min.
The reactions were analyzed using denaturing 15% polyacrylamide gels and autoradiography.

RESULTS
The DGCR8 P351A Mutant Can Be Expressed as Hemebound and Heme-free Dimers—Pro-351 is located close to the
proposed heme-binding surface of DGCR8 in three-dimensional space (19). We mutated Pro-351 to alanine in the context
of NC1 (P351A) and examined the ability of this mutant to bind
heme by expressing it in E. coli with and without the addition of
␦-ALA, a heme biosynthesis intermediate. In both cases, P351A
was present in dimeric and monomeric forms, as indicated by
SEC (Fig. 1, B and C). When overexpressed without ␦-ALA,
P351A was nearly completely free of heme (Fig. 1B). When
␦-ALA was added to the bacterial culture at the time of induction, the heme occupancy of the P351A dimer was increased to
nearly the level of the wild type under the same conditions;
however, the P351A monomer remained free of heme (Fig. 1C).
The heme-bound P351A dimer, purified using SEC, exhibited
an electronic absorption spectrum with peaks at 365, 447, and
556 nm, similar to those of the wild-type NC1 protein (Fig. 1C).
The P351A mutation caused a 3-nm blue shift of the 450-nm
Soret peak, indicating some alteration in the local structure of
the NC1 protein. In the presence of ␦-ALA, the wild-type NC1
is expressed nearly exclusively as a heme-bound dimer (10),
suggesting that the P351A mutation may reduce the affinity of
DGCR8 for heme. Overall, these results suggest that the complex of P351A with heme retains a structure similar to that of
the wild type.
Heme Dissociates from Wild-type DGCR8 Extremely Slowly,
and the P351A Mutation Increases the Dissociation Rate—To
determine the stability of the DGCR8-heme complex, we performed a heme dissociation assay by incubating heme-bound
NC1 with 5-fold molar excess of horse apomyoglobin. Apomyoglobin has an extremely high affinity for heme, with KD of
⬃3 ⫻ 10⫺15 M (25). Thus, heme molecules dissociated from
NC1 were quickly bound to apomyoglobin, and this transfer
was accompanied by a shift of the Soret peak from ⬃450 to 414
nm (Fig. 2A). At room temperature, heme dissociated from the
P351A dimer within 1–2 h (Fig. 2A). When the absorbance at
447 nm was plotted over time, the data fit nicely to a one-phase
VOLUME 286 • NUMBER 19 • MAY 13, 2011

DGCR8 Is a Double-cysteine-ligated Heme Protein
exponential decay function, giving an estimated dissociation
rate constant (koff) of 5.0 ⫾ 0.1 ⫻ 10⫺4 s⫺1. The increase in
absorbance at 414 nm over time gave a similar value (5.8 ⫾
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FIGURE 1. Characterization of the NC1 P351A mutant. A, domain structure
of human DGCR8. The double-stranded RNA-binding domains (dsRBD) and
C-terminal tail (CTT) are required and sufficient for cooperative association
with pri-miRNAs and for triggering cleavage by the Drosha nuclease. The
human NC1, HBD-His6 and frog HBD-His6 protein constructs used in this study
are represented by the brackets. B, size exclusion chromatogram of NC1
P351A overexpressed in E. coli. The 367-nm absorption trace overlaps with
the 450-nm one and thus is omitted from the chromatogram drawing. D and
M indicate the dimer and monomer peaks. An electron absorption spectrum
of the dimer peak is shown (right). C, same as B, except that 1 mM ␦-ALA was
added to the bacterial culture at induction.

0.4 ⫻ 10⫺4 s⫺1). In contrast, incubation of wild-type hemebound NC1 with apomyoglobin did not result in any shift of the
Soret peak even after 4 days (Fig. 2C). This observation suggests
either extremely slow dissociation of heme from the wild-type
NC1 (with t1/2 ⬎⬎ 4 days or koff ⬍⬍ 3 ⫻ 10⫺6 s⫺1) or a higher
affinity of wild-type NC1 for heme than that of apomyoglobin.
By comparison, the koff for sperm whale myoglobin is 8.4 ⫻
10⫺7 s⫺1, that for human hemoglobin is 7.1 ⫻ 10⫺6 s⫺1 (26, 27),
and the koff for the single-cysteine-ligated heme-sensor proteins such as heme-regulated inhibitor and neuronal PAS protein 2 (NPAS2) are typically 1– 6 ⫻ 10⫺3 s⫺1 (21). The hemesensor proteins are a group of heme-binding proteins in which
the activity is regulated either directly by heme or by signaling
gas molecules such as NO and CO. The slow dissociation of
heme from NC1 argues against a model in which activity of
DGCR8 is reversibly regulated by its association with heme.
Furthermore, the P351A mutation increases the dissociation
rate of the heme from NC1, possibly by altering the conformation of the loop containing Cys-352.
The P351A-Heme Complex Can Be Reconstituted Using Ferric Heme—It has not been possible to reconstitute the DGCR8heme complex by incubating heme with the NC1 monomer, the
only heme-free form of the wild-type protein currently available. We wondered whether the heme-free P351A dimer would
bind heme in vitro. We titrated ferric heme into the heme-free
P351A dimer and found that they readily formed a specific
complex. The P351A-heme complex displayed absorption
peaks at 365, 447, and 556 nm (Fig. 3A), nearly identical in
positions and relative intensities to those of the heme-bound
P351A dimer purified from E. coli. As the total ferric heme concentration increased, the 447-nm and 556-nm absorption plateaued after ⬃4.5 M (Fig. 3, A and B), close to the P351A dimer
concentration of 4.35 M. This result suggests that each P351A
dimer binds one ferric heme molecule. The same protein-heme
stoichiometry was previously observed for the wild-type NC1
dimer when it was characterized using HPLC and mass spectrometry (10). In contrast, the absorbance at 365 nm continued
to increase linearly after the specific heme-binding site of
P351A had been saturated (Fig. 3B). Both specific and nonspe-
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FIGURE 2. Heme dissociates from the wild-type NC1 slowly, and P351A increases the rate. Heme-bound NC1, either P351A (A and B) or wild-type (C), was
incubated with a 6-fold excess of apomyoglobin at 25 °C. A, electronic absorption spectra obtained at 0, 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, and 90 min. B, the
414-nm (metmyoglobin) and 447-nm (P351A-heme complex) values shown in A were fit to a single exponential function. The rates shown are mean ⫾ S.D. of
three independent repeats. C, wild-type NC1 showed no significant changes of absorbance at 414 nm and 450 nm at room temperature over 4 days.
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cific NC1-heme interactions appear to contribute to the
365-nm peak (see below). The reconstituted P351A dimer-ferric heme complex was analyzed using SEC. The absorbances at
280, 370 and 450 nm coeluted in a peak with an elution volume
similar to those of the heme-bound and heme-free P351A
dimers, indicating that the complex was stable and remained as
a dimer (Fig. 3C). In contrast to the dimer, the heme-free P351A
monomer is incapable of binding ferric heme. Incubation of the
heme-free P351A monomer with ferric heme yielded an
absorption peak at 372 nm and no Soret peak at ⬃450 nm (Fig.
3D), indicative of nonspecific heme binding. SEC of the hemefree P351A monomer incubated with ferric heme showed that
the protein did not coelute with heme (supplemental Fig. S1).
Thus, the heme-free P351A monomer cannot bind heme and
convert to the heme-bound dimer under the conditions tested.
These results confirm the previous finding that dimerization of
DGCR8 is required for association with heme (10). Importantly,
the in vitro heme-binding assays of the P351A dimer were performed in the absence of CO (Fig. 3A). The fact that DGCR8
binds ferric heme without CO to give a Soret peak at ⬃450 nm
clearly demonstrates that it must bind heme through a set of
interactions distinct from those in ferrous cytochrome P450
bound by CO.
The Hyperporphyrin Spectrum of DGCR8 Matches Those of
Ferric Heme with Two Thiolate Ligands—How does DGCR8
interact with ferric heme to generate the 450-nm absorption
peak? The similarly intense absorption peaks at ⬃450 nm and
⬃366 nm in the DGCR8-heme complexes constitute a hyper-
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porphyrin (split Soret) spectrum. Early studies showed that
having a ferrous heme ligated with a cysteine (thiolate) and CO
is not the only way to obtain a hyperporphyrin spectrum. Ferric
heme in complex with two mercaptide ligands, used as model
compounds for hemoproteins, can produce a hyperporphyrin
spectrum with the split Soret bands of approximately equal
intensity (28). Similarly, ligation of an exogenous thiolate or
phosphine compound to ferric heme-thiolate proteins, such as
cytochrome P450CAM and chloroperoxidase, also generates
hyperporphyrin spectra with two equally intense Soret bands
(supplemental Table S1) (29 –31). The electronic absorption
spectrum of the NC1-heme complex bears a striking similarity
to that of chloroperoxidase with an exogenous thiolate ligand
(Fig. 4). Additionally, these studies on cytochrome P450CAM
and chloroperoxidase showed a broad ␣/␤ band with its maximum at ⬃560 nm, similar to the 556-nm peak in the electronic
absorption spectrum of the NC1-heme complex (29 –31). The
match of these electronic absorption spectroscopic signatures
suggests that DGCR8 likely binds ferric heme using a cysteine
thiolate as the fifth ligand and a sixth ligand that could be either
a thiolate or a phosphine. Unlike cytochrome P450 and chloroperoxidase, DGCR8 (both NC1 and HBD-His6) can be purified and stored in the absence of any exogenous thiolate- or
phosphine-containing compounds and still maintain its hyperporphyrin spectrum, suggesting that DGCR8 mostly likely uses
two endogenous ligands. These ligands could be the side chain
of a cysteine (thiolate or thiol) or a methionine (an electron
donor similar to the phosphine).
VOLUME 286 • NUMBER 19 • MAY 13, 2011
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FIGURE 4. The hyperporphyrin spectrum of DGCR8 likely results from
double-cysteine ligation to ferric heme. The electronic absorption spectrum of ferric heme-bound NC1 dimer (solid line) is strikingly similar to that of
the ferric chloroperoxidase complexed with ethyl-2-mercaptoacetate
(dashed line). The latter spectrum was reproduced from an earlier work (31).

MCD and EPR Spectra Reveal Spin, Oxidation, and Coordination States of the Heme in DGCR8—We performed MCD and
EPR spectroscopies to further interrogate the chemical environment of the heme in DGCR8. Because these techniques
require large amounts of protein, we chose to use the C-terminal His6-tagged heme-binding domain (HBD-His6) from frog
DGCR8 (Fig. 1A), which can be expressed and purified with a
yield of ⬃1 mg per liter of bacterial culture. The HBD sequences
of human and frog DGCR8 are 80% identical. The electronic
absorption spectrum of the frog DGCR8 HBD-His6 (Fig. 5,
upper panel) is nearly identical to those of the human DGCR8
NC1 and HBD-His6 (19) proteins, indicating a close similarity
between the chemical environments of their heme cofactors.
The MCD spectrum of the frog DGCR8 HBD-His6 protein,
recorded at 4 K, is dominated by two features with peak-crossover-trough positions of 344-368-388 nm and 430-435-448 nm,
respectively (Fig. 5, lower panel). These features correspond to
the blue-shifted and red-shifted split Soret bands in the absorption spectrum. Weaker features are observed in the MCD spectrum between 500 and 750 nm that correspond to the ␣/␤ (557
nm) and ligand-to-metal charge-transfer transition (660 nm)
peaks in the absorption spectrum. The MCD spectrum of the
frog HBD-His6 bears the greatest resemblance to MCD spectra
of ferric chloroperoxidase and ferric P450CAM to which either
methanethiol or bis(hydroxymethyl)methylphosphine has
been added (5, 31, 32), further supporting the model in which
the heme iron in DGCR8 is six-coordinate with one cysteine
thiolate ligand, and a sixth ligand that may be either another
cysteine (equivalent to the methanethiol) or a methionine (similar to the phosphine). To probe the electronic state of the metal
iron, MCD spectra of the frog HBD-His6 were recorded over a
range of temperatures (4 –50 K). Notably, all of the MCD signals are temperature-dependent, indicating that they originate
from a paramagnetic metal. MCD signals at the most intense
feature (448 nm) were monitored over a range of magnetic field
intensities at several temperatures (2.5–25 K). The resulting
magnetic saturation curves at the different temperatures overlap each other (supplemental Fig. S2), indicating that the spin
state of the iron is S ⫽ 1⁄2. This result implies that the heme in
DGCR8 contains low-spin Fe(III), with only one unpaired
electron.
MAY 13, 2011 • VOLUME 286 • NUMBER 19

FIGURE 5. Electronic absorption and MCD spectra of the ferric hemebound frog DGCR8 HBD-His6. The electronic absorption spectrum (top
panel) was taken at room temperature using the dimeric frog HBD-His6 at 12.2
M concentration in a buffer containing 50 mM EPPS (pH 8.0) and 400 mM
NaCl. As a control, an electronic absorption spectrum was also recorded at 4 K
and displayed no differences in peak positions and intensity (data not
shown). The MCD spectrum (bottom panel) was recorded using a protein sample at 24.5 M in 22.5 mM EPPS (pH 8.0), 180 mM NaCl, and 55% (v/v) glycerol.

FIGURE 6. EPR spectrum of the ferric heme-bound frog DGCR8 HBD-His6
protein. The frog HBD-His6 protein (153 M) was in 50 mM EPPS (pH 8.0) and
400 mM NaCl. The spectrum represents an average of 10 scans taken at 10 K,
with 9.383 GHz microwave frequency, 8.000 G modulation amplitude, 100
kHz modulation frequency, 60 dB receiver gain, 163.84 ms time constant, and
a power of 1.002 milliwatt. The asterisk represents a signal present in the
cavity.

The EPR spectrum of frog DGCR8 HBD-His6 further supports the conclusion that the heme iron is low-spin Fe(III).
When the spectrum was scanned from 0 –10,000 G, the only
signal observed was a narrow rhombic signal centered at ⬃2900
G (data not shown). A narrow scan (2000 – 4000 G) around this
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 7. The sixth ligand to ferric heme in DGCR8 is not a methionine. A, mass spectra of native and SeMet-labeled frog DGCR8 HBD-His6 indicates nearly
complete substitution of Met by SeMet. The difference in their m/z peaks, 239, is consistent with all five methionine residues substituted with SeMet. B, the
normalized electronic absorption spectrum of the SeMet-substituted frog HBD-His6 is nearly identical to that of the native protein (Fig. 5, top panel). C, the normalized
MCD spectrum of the SeMet-substituted frog HBD-His6 is nearly identical to that of the native protein (Fig. 5, bottom panel). D, comparison of the EPR spectra of the
native and SeMet-labeled frog HBD-His6. The spectral parameters for the SeMet-labeled frog HBD-His6 were the same as those of the native listed in Fig. 6, except that
the ferric heme concentration of the sample was 142 M and the spectrum was acquired with a 9.384 GHz microwave frequency.

rhombic signal gave the three g values: gz ⫽ 2.60, gy ⫽ 2.27, and
gx ⫽ 1.84 (Fig. 6). The presence of a single rhombic signal in the
g ⫽ 2 region reveals that the iron in DGCR8 is clearly low spin
Fe(III). Analysis of the calculated crystal field parameters of
tetragonality (⌬/, degree of electronic donation at the iron
center) and rhombicity (V/⌬, degree of geometric distortion of
the iron center) places the frog Fe(III) HBD-His6 in the same
region as native ferric chloroperoxidase in the Blumberg-Peisach “truth” diagrams (33), in closest proximity to Fe(III)
chloroperoxidase thiol adducts such as thioacetic acid and
␤-mercaptoethanol and the Fe(III) chloroperoxidase bis(hydroxymethyl)methyl phosphine adduct (32, 34) (supplemental Table S2 and Fig. S3). Although a number of thiol adducts
of ferric chloroperoxidase and ferric P450CAM display multiple overlapping, rhombic EPR signals, the frog Fe(III)
HBD-His6 only displays a single rhombic signal, suggesting a
well defined, homogenous environment about the DGCR8
heme.
The Sixth Axial Ligand of Heme in DGCR8 Is Not a
Methionine—Because both thiols and phosphines ligated to ferric chloroperoxidase and P450 generate hyperporphyrin spectra (5, 32), we considered the possibility that one of the ligands
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coordinated to the heme in DGCR8 is the thioether of a methionine side chain. We examined the spectroscopic properties of
the frog HBD-His6 labeled with SeMet, with the expectation
that if methionine were a ligand to the heme iron, its substitution with the selenium analog would be evident in the heme
spectra. A MALDI-TOF mass spectrum of the SeMet-labeled
HBD-His6 showed a single major peak with a m/z value greater
than that of the unlabeled protein by 239, within experimental
error (ⱕ ⫾ 13) of the expected increase of 234 when all five
methionine residues in the frog HBD-His6 sequence are substituted with SeMet (Fig. 7A). This result indicated that nearly
complete substitution of methionine with SeMet was achieved.
Importantly, the electronic absorption spectrum of SeMet-labeled frog HBD-His6 shows no changes in peak positions relative to the native construct (Fig. 7B). In contrast, previous studies showed that substitution of a methionine ligand with SeMet
caused the Soret ␣ and ␤ peaks to red-shift on the range of 3–7
nm (35, 36). The signals in the MCD and EPR spectra of SeMetlabeled HBD-His6 were also unchanged from those of the native
Met-containing protein (Fig. 7, C and D). The large difference
in spin-orbit coupling between Se and S is expected to give rise
to significantly different spectral features; that the MCD and
VOLUME 286 • NUMBER 19 • MAY 13, 2011
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FIGURE 8. Cys-352 from both subunits in a DGCR8 dimer serve as the axial
ligands to ferric heme. Electronic absorption spectra of hHBDC430S (10 M)
titrated with MeHgAc. The MeHgAc was added at steps of 0.5 molar equivalent of ferric heme-bound HBD dimer. The spectra of the starting point (0
molar equivalent of MeHgAc) and end point (2.5 molar equivalents) are
shown in solid traces and the intermediate steps in dotted lines. After the
MeHgAc titration, 1.2 molar equivalents of apomyoglobin (relative to the
HBD dimer) were added, and the electronic absorption spectrum was
immediately recorded (dashed line). The inset shows absorbance at 450 nm
over the course of the titration.

EPR spectra of the two proteins are the same argues that methionine is not the sixth ligand to the heme in DGCR8. Thus,
DGCR8 must use two endogenous cysteine residues to ligate
heme.
Cys-352 from both Subunits in a DGCR8 Dimer Serve as the
Axial Ligand of Heme—Which cysteine residues does DGCR8
use for ligating heme? There are seven cysteine residues in the
NC1 (human) sequence; however, only two of them, Cys-352
and Cys-430, are located in the HBD region. Available data
suggest that the HBD binds heme in the same way as NC1 (19)
and that Cys-430 is not required for association with heme (10).
Thus, Cys-352 is the only cysteine residue in human DGCR8
that can serve as a ligand for heme. Furthermore, heme binds to
dimeric DGCR8, suggesting a model in which the two Cys-352
from both subunits serve as the axial ligands of heme.
We directly tested this model using a mercury titration strategy. Mercury compounds bind thiol groups with high affinities
and thus can disrupt the interaction between cysteine ligands
and the heme cofactor. To simplify the interpretation, we first
mutated Cys-430 to serine in the context of human DGCR8
HBD-His6 (hHBDC430S) so that Cys-352 was the only cysteine
present in the sequence. Not surprisingly, the mutant exhibited
an electronic absorption spectrum with peak positions and relative intensities indistinguishable from those of the wild-type
protein (Fig. 8). This result confirms experimentally that CysMAY 13, 2011 • VOLUME 286 • NUMBER 19

352 is the only cysteine residue that can ligate heme. Titration
of the hHBDC430S dimer with MeHgAc led to a linear decrease
of the peaks at 366, 450, and 556 nm until 2.0 molar equivalents
(relative to hHBDC430S dimer) was reached. The peaks disappeared completely after addition of 2.5 molar equivalents of
MeHgAc (Fig. 8). Concomitantly, there appeared a broad electronic absorption peak centered at 385 nm resembling that of
free ferric heme (Fig. 8), suggesting that the heme was released
from hHBDC430S after both Cys-352 ligands dissociated from
the heme iron. Consistent with this interpretation, when 1.2
molar equivalents of apomyoglobin were added to the mercurytreated hHBDC430S dimer, the Soret peak shifted to 409 nm,
characteristic of ferric myoglobin (metmyoglobin). Because
each methylmercury generally binds one cysteine in a protein,
these results indicate that both Cys-352 residues in the
hHBDC430S dimer are important for association with heme.
Heme Binds to DGCR8 Expressed in Eukaryotic Cells—We
have studied the DGCR8-heme interaction using overexpression in E. coli or biochemical reconstitution; however, the question remains: does this family of proteins, found only in animals, bind heme in eukaryotic cells? Because overexpression of
DGCR8 in mammalian cells is subjected to multiple levels of
regulation (37) and appears to be cytotoxic, we addressed this
question by expressing NC1 with a N-terminal His6 tag (His6NC1) in Sf9 insect cells (Fig. 9). The purified His6-NC1 protein,
which appeared largely as a single band, displayed absorption
peaks at 366, 450, and 556 nm (Fig. 9A), identical to those of the
NC1-ferric heme complex expressed in bacteria. This His6NC1 protein sample was further analyzed using SEC (Fig. 9B).
The chromatogram showed that the insect cell-expressed His6NC1 eluted at a volume expected for the NC1 dimer, and no
monomer peak was visible, suggesting that the His6-NC1
existed nearly exclusively as a dimer. SEC also allowed the small
amounts of protein and nucleic acid impurities to be removed
from His6-NC1. Based on the absorbance ratio A450/A280, the
heme occupancy of the insect cell-expressed His6-NC1 was
estimated to be ⬃50%. We tested the His6-NC1 using reconstituted pri-miRNA processing assays. This assay revealed that
the activity of the Sf9-expressed His6-NC1 was comparable
with that of the heme-bound NC1 dimer expressed in bacteria
(Fig. 9C). Given these data, we conclude that active DGCR8
proteins expressed in eukaryotic cells can bind heme.

DISCUSSION
Here we present biochemical and spectroscopic characteristics of the DGCR8-heme complex, revealing interactions distinct from those of other known cysteine-ligated hemoproteins.
The DGCR8-heme complex displays an absorption spectrum
with an intense peak near 450 nm in the absence of CO. Our
data reveal that the heme iron is in the ferric state and that
DGCR8 ligates to the heme iron using two endogenous cysteine
side chains (Fig. 10).
Our recent crystal structure of the N-terminal dimerization
subdomain of the human DGCR8 HBD revealed a symmetric
dimer with an extensive dimerization interface mediated
mostly by hydrophobic interactions (19). Although our structure does not contain heme, it shows that the two Cys-352 residues in the dimer are within van der Waals contacting distance
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 10. Schematic of how the DGCR8 HBD binds ferric heme.

of each other. A conformational change of the loop containing
Cys-352 likely occurs upon association of the protein with
heme and should be able to position the two Cys-352 side
chains on opposite sides of the heme plane for axial ligation.
Here we show that the DGCR8-heme complexes are remarkably stable (Fig. 2C). Proper positioning of the two Cys-352 side
chains within a robust dimer likely contributes to this stability.
This study establishes DGCR8 as the first example of a heme
protein with two endogenous cysteines, Cys-352 from both
subunits, as axial ligands. Our investigation revealed that Pro351 is important for the stability of the DGCR8-heme complex.
Pro-351 and Cys-352 together are similar to the heme regulatory motif, which contains a Cys-Pro sequence but in the opposite order. Heme regulatory motifs directly bind heme and are
found in repeats in a range of heme-regulated proteins, such as
the yeast transcription activator HAP1 and the human ␦-aminolevulinic acid synthase, heme oxygenase-2, heme-regulated
eukaryotic initiation factor 2␣ kinase, and Rev-erb␤ (38 – 42). It
is possible that in both motifs the proline helps to position the
cysteine side chain in an appropriate geometry for ligation and
for either catalytic or regulatory functions. However, unlike the
heme regulatory motifs, the Pro-351 and Cys-352 residues are
not sufficient for DGCR8 to associate with heme, because
dimerization and Trp-329 in the WW motif are also required
for heme binding.
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Our previous (10) and current studies clearly demonstrated
that dimerization is required for association with heme. The
heme-free forms of NC1 expressed in E. coli are either mostly
monomeric (for the wild type and the C351A mutant) (10) or a
mixture of monomers and dimers (for P351A, this study). We
have never observed monomeric NC1 to bind heme and
dimerize in vitro, regardless of whether it is the wild type or the
P351A mutant, (Fig. 3D and data not shown). Furthermore, it
appears that the monomeric species of NC1 is only generated in
E. coli and not in insect cells (Fig. 9B). A careful inspection of
the SDS-12% polyacrylamide gels of the bacteria-expressed
NC1 revealed that the monomer contained low-molecularweight protein species comigrating with the dye bromphenol
blue (supplemental Fig. S4, A and B). On a SDS-15% polyacrylamide gel, these protein species appeared as an approximately
10-kDa band with a smear underneath (supplemental Fig. S4C),
indicating that they are heterogeneous. Furthermore, our crystal structure of the N-terminal sub-domain of human DGCR8
HBD shows an extensive dimerization interface that does not
appear to be easily disrupted in non-denaturing conditions.
Thus, the “monomeric” NC1 may partially, if not entirely, consist of heterodimers in which one subunit has been non-specifically cleaved in the central loop region (19) of its HBD, in the
E. coli cells or during purification, into a fragment that retains
the dimerization domain. It is possible that in human cells both
heme-free and heme-bound DGCR8 are dimers.
The current study reveals important features of the DGCR8heme interaction that will help us to understand its potential
physiological function in regulating miRNA maturation. We
have two working models. In the first model, the DGCR8-heme
complex may serve as a sensor for cellular or environmental
signals (the heme-based sensor model) (43). In a heme-based
sensor, heme is stably bound to a protein partner, which is
consistent with the slow dissociation of heme from NC1
observed here (Fig. 2C). In the second, heme itself may serve as
VOLUME 286 • NUMBER 19 • MAY 13, 2011
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the ligand to activate miRNA processing (the heme sensing
model) (21). The slow dissociation of heme from NC1 argues
against a heme sensing model in which heme reversibly binds to
DGCR8 and regulates its activity. However, it is still possible
that heme may bind and activate DGCR8 while the signal is
turned off through protein degradation.
Acknowledgments—We thank J. Feigon and T. C. Brunold for generously sharing UV/visible and MCD spectrophotometers, J. Loo for
access to equipment in the University of California at Los Angeles
Mass Spectrometry and Proteomics Technology Center, J. Dawson, S.
Merchant and A. Smith for discussion, and J.P. Jacob and V. Kickhoefer for technical assistance.
REFERENCES
1. Perutz, M. F., Wilkinson, A. J., Paoli, M., and Dodson, G. G. (1998) Annu.
Rev. Biophys. Biomol. Struct. 27, 1–34
2. Derbyshire, E. R., and Marletta, M. A. (2009) Handb. Exp. Pharmacol. 191,
17–31
3. Ortiz de Montellano, P. R. (2000) Curr. Opin. Chem. Biol. 4, 221–227
4. Ortiz de Montellano, P. R. (2004) Cytochrome P450: Structure, Mechanism, and Biochemistry, 3rd Ed., Springer, New York
5. Dawson, J. H., and Sono, M. (1987) Chem. Rev. 87, 1255–1276
6. Rousseau, D. L., Li, D., Couture, M., and Yeh, S. R. (2005) J. Inorg. Biochem.
99, 306 –323
7. Udit, A. K., and Gray, H. B. (2005) Biochem. Biophys. Res. Commun. 338,
470 – 476
8. Dawson, J. H. (1988) Science 240, 433– 439
9. Paoli, M., Marles-Wright, J., and Smith, A. (2002) DNA Cell. Biol. 21,
271–280
10. Faller, M., Matsunaga, M., Yin, S., Loo, J. A., and Guo, F. (2007) Nat. Struct.
Mol. Biol. 14, 23–29
11. Denli, A. M., Tops, B. B., Plasterk, R. H., Ketting, R. F., and Hannon, G. J.
(2004) Nature 432, 231–235
12. Gregory, R. I., Yan, K. P., Amuthan, G., Chendrimada, T., Doratotaj, B.,
Cooch, N., and Shiekhattar, R. (2004) Nature 432, 235–240
13. Han, J., Lee, Y., Yeom, K. H., Kim, Y. K., Jin, H., and Kim, V. N. (2004)
Genes Dev. 18, 3016 –3027
14. Landthaler, M., Yalcin, A., and Tuschl, T. (2004) Curr. Biol. 14, 2162–2167
15. Lee, Y., Ahn, C., Han, J., Choi, H., Kim, J., Yim, J., Lee, J., Provost, P.,
Rådmark, O., Kim, S., and Kim, V. N. (2003) Nature 425, 415– 419
16. Kim, V. N., Han, J., and Siomi, M. C. (2009) Nat. Rev. Mol. Cell Biol. 10,
126 –139

MAY 13, 2011 • VOLUME 286 • NUMBER 19

17. Faller, M., and Guo, F. (2008) Biochim. Biophys. Acta 1779, 663– 667
18. Faller, M., Toso, D., Matsunaga, M., Atanasov, I., Senturia, R., Chen, Y.,
Zhou, Z. H., and Guo, F. (2010) RNA 16, 1570 –1583
19. Senturia, R., Faller, M., Yin, S., Loo, J. A., Cascio, D., Sawaya, M. R., Hwang,
D., Clubb, R. T., and Guo, F. (2010) Protein Sci. 19, 1354 –1365
20. Omura, T. (2005) Biochem. Biophys. Res. Commun. 338, 404 – 409
21. Igarashi, J., Kitanishi, K., Martinkova, M., Murase, M., Iizuka, A., and
Shimizu, T. (2008) Acta Chim. Slov. 55, 67–74
22. Stern, J. O., and Peisach, J. (1974) J. Biol. Chem. 249, 7495–7498
23. Van Duyne, G. D., Standaert, R. F., Karplus, P. A., Schreiber, S. L., and
Clardy, J. (1993) J. Mol. Biol. 229, 105–124
24. Gasteiger, E., Gattiker, A., Hoogland, C., Ivanyi, I., Appel, R. D., and Bairoch, A. (2003) Nucleic Acids Res. 31, 3784 –3788
25. Hargrove, M. S., Krzywda, S., Wilkinson, A. J., Dou, Y., Ikeda-Saito, M.,
and Olson, J. S. (1994) Biochemistry 33, 11767–11775
26. Hargrove, M. S., Barrick, D., and Olson, J. S. (1996) Biochemistry 35,
11293–11299
27. Hargrove, M. S., Singleton, E. W., Quillin, M. L., Ortiz, L. A., Phillips, G. N.,
Jr., Olson, J. S., and Mathews, A. J. (1994) J. Biol. Chem. 269, 4207– 4214
28. Ruf, H. H., and Wende, P. (1977) J. Am. Chem. Soc. 99, 5499 –5500
29. Yu, C., Gunsalus, I. C., Katagiri, M., Suhara, K., and Takemori, S. (1974)
J. Biol. Chem. 249, 94 –101
30. Sono, M., Andersson, L. A., and Dawson, J. H. (1982) J. Biol. Chem. 257,
8308 – 8320
31. Sono, M., Dawson, J. H., and Hager, L. P. (1984) J. Biol. Chem. 259,
13209 –13216
32. Sono, M., Dawson, J. H., and Hager, L. P. (1985) Inorg. Chem. 24,
4339 – 4343
33. Blumberg, W. E., and Peisach, J. (1971) Adv. Chem. 100, 271–291
34. Sono, M., Hager, L. P., and Dawson, J. H. (1991) Biochim. Biophys. Acta
1078, 351–359
35. Wallace, C. J., and Clark-Lewis, I. (1992) J. Biol. Chem. 267, 3852–3861
36. Low, D. W., Hill, M. G., Carrasco, M. R., Kent, S. B., and Botti, P. (2001)
Proc. Natl. Acad. Sci. U.S.A. 98, 6554 – 6559
37. Han, J., Pedersen, J. S., Kwon, S. C., Belair, C. D., Kim, Y. K., Yeom, K. H.,
Yang, W. Y., Haussler, D., Blelloch, R., and Kim, V. N. (2009) Cell 136,
75– 84
38. Zhang, L., and Guarente, L. (1995) EMBO J. 14, 313–320
39. McCoubrey, W. K., Jr., Huang, T. J., and Maines, M. D. (1997) J. Biol.
Chem. 272, 12568 –12574
40. Yi, L., and Ragsdale, S. W. (2007) J. Biol. Chem. 282, 21056 –21067
41. Igarashi, J., Murase, M., Iizuka, A., Pichierri, F., Martinkova, M., and Shimizu, T. (2008) J. Biol. Chem. 283, 18782–18791
42. Gupta, N., and Ragsdale, S. W. (2011) J. Biol. Chem. 286, 4392– 4403
43. Gilles-Gonzalez, M. A., and Gonzalez, G. (2005) J. Inorg. Biochem. 99,
1–22

JOURNAL OF BIOLOGICAL CHEMISTRY

16725

